Study on the effect of plasmapheresis combined with high dose of IVIG reduces donor-specific HLA antibody titer to promote donor cell implantation in allogeneic hematopoietic stem cell transplantation

Start Date28 Nov 2023

Sponsor / Collaborator

The General Hospital of Western Theater Command

JPRN-jRCT2041220136

/ RecruitingPhase 3IIT

A multicenter, open-label study to investigate the efficacy and safety of GB-0998 for the treatment of neurological neuropathy in patients with Eosinophilic Granulomatosis with Polyangiitis(EGPA).

Start Date15 Jan 2023

Sponsor / Collaborator-

ChiCTR2200062896

/ SuspendedNot ApplicableIIT

A multicenter study of a short-course blood purification sequential reduction IVIG regimen for the treatment of severe autoimmune diseases

Start Date01 Sep 2022

Sponsor / Collaborator-

100 Clinical Results associated with Human Normal Immunoglobulin (The Japan Blood Products Organization)

100 Translational Medicine associated with Human Normal Immunoglobulin (The Japan Blood Products Organization)

100 Patents (Medical) associated with Human Normal Immunoglobulin (The Japan Blood Products Organization)

8,973

Literatures (Medical) associated with Human Normal Immunoglobulin (The Japan Blood Products Organization)

31 Dec 2025·Hematology

Sustained response off treatment after fostamatinib in refractory immune thrombocytopenia: A series of four case reports

Article

Author: Ghanima, Waleed ; Rackwitz, Stefan ; Lucas Boronat, Francisco Javier ; Carrai, Valentina

INTRODUCTION:

A goal of most primary immune thrombocytopenia (ITP) treatments is reducing or discontinuing treatment while maintaining a response including an absence of bleeding events. We present four cases describing treatment with the spleen tyrosine kinase (SYK) inhibitor, fostamatinib, that showed sustained response off treatment (SROT).

CASE PRESENTATIONS:

Case 1 was a 66-year-old male with chronic ITP. He was pre-treated with prednisone and rituximab before being in the FIT-2 clinical trial (placebo). He received fostamatinib in the FIT-3 open-label extension for seven weeks and maintained SROT for 2.5 years. Case 2 was a 54-year-old female patient with chronic, highly refractory ITP. SROT was achieved after 6 months of fostamatinib and was maintained for more than 16 months (in remission to date). Case 3 was a 60-year-old male with chronic ITP. He was successfully treated with cycles of corticosteroids for six years prior to fostamatinib. He was treated with fostamatinib plus prednisone for approximately two months. SROT was observed in this patient for one year. Case 4 was a 67-year-old male with persistent ITP. Before fostamatinib, he was unresponsive to high-dose dexamethasone, IVIG, eltrombopag and romiplostim. After 11 months of fostamatinib, his dose was tapered for three months and ultimately discontinued. SROT was observed for more than ten months (in remission to date).

DISCUSSION:

These cases emphasize that SROT is achievable with fostamatinib in complex ITP cases unresponsive to multiple previous therapies. Additional research is needed to identify the magnitude of the underlying mechanisms, and the clinical factors associated with, and potentially predictive of, SROT.

31 Dec 2025·Hematology

The costs of treating bleeding episodes in patients with immune thrombocytopaenia in the United Kingdom

Article

Author: McDonald, Vickie ; James, Samuel ; Pochopień, Michał ; Zakrzewski, Maja ; Guterres, Sebastian

OBJECTIVES:

Immune thrombocytopaenia (ITP) is a rare autoimmune disorder characterized by low platelet count and increased risk of bleeding. This study aimed to be the first publication to characterize the economic burden of bleeding events in patients with ITP in the UK.

METHODS:

We performed a microcosting analysis to estimate the costs associated with bleeding events in patients with ITP. Healthcare resources utilized in the management of bleeds of different severity were costed using well-established UK cost sources. The results were validated through semi-structured interviews with clinical experts.

RESULTS:

The severity of bleeding events was classified into four categories, ranging from bleeding managed at home, through mild bleeding managed in the outpatient or day case setting, to serious and life-threatening bleeding events requiring inpatient admission. Total medical costs per event ranged from £2,930 for managing a mild bleeding event, through £16,711 for a serious bleeding event to £32,461 for a life-threatening event. The major cost driver for mild and serious events were intravenous immunoglobulin (IVIg) costs, amounting to £1,614 and £8,071 for the two severity categories, respectively. For life-threatening events, the costs of intensive care unit stay (£9,089) exceeded those of IVIg (£8,071).

CONCLUSION:

Real-world costs of managing bleeding in patients with ITP in the UK are substantial and greater than costs set only based on the UK NHS Tariff. Mitigating the risk of bleeding in patients with ITP is likely to yield not only clinical advantages for patients but also offer substantial cost savings to the health system.

31 Dec 2025·PLATELETS

A case with a novel GATA1 variant mimicking immune thrombocytopenia attacks

Article

Author: Aktekin, Elif Habibe ; Ceylaner, Serdar ; Erbay, Ayşe ; Beşen, Şeyda ; Yazıcı, Nalan

One of the leading thrombocytopenia occasions in childhood is immune thrombocytopenia (ITP). Small number of these patients do not respond to treatment methods known to be effective for ITP such as corticosteroids, intravenous immunoglobulin and thrombopoietin receptor agonists (eltrombopag, romiplostim, etc.) and have serious bleeding symptoms. We present a case in which a molecular genetic analysis was performed due to challenging responses to medical treatment for severe systemic bleeding symptoms which were similar to ITP. A hemizygous variant was detected in the GATA1 gene and a homozygous variant in the ATP2A1 gene for Brody myopathy. Eltrombopag, romiplostim, IVIG and corticosteroid were applied to resistant thrombocytopenia of the patient without knowing the cause. Patient had response in platelet counts in some occasions. This situation attracted our attention after the detection of this GATA variant in the etiopathogenesis of thrombocytopenia. Further investigations should be performed for much more rare causes of thrombocytopenia in patients with refractory thrombocytopenia attacks.

News (Medical) associated with Human Normal Immunoglobulin (The Japan Blood Products Organization)

14 May 2025

·www.businesswire.com

Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 Data

MENLO PARK, Calif.--(BUSINESS WIRE)--Nuvig Therapeutics, Inc. (“Nuvig”), a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, today announced that the first patient has been dosed in its Phase 2 clinical trial evaluating NVG-2089 in individuals with chronic inflammatory demyelinating polyneuropathy (CIDP). The company also announced that it will present results from a Phase 1 study of NVG-2089 in healthy volunteers at the 2025 Peripheral Nerve Society (PNS) Annual Meeting on May 19th in Edinburgh, Scotland. “Dosing the first patient in our Phase 2 CIDP trial marks an important step forward in our mission to deliver targeted, mechanism-based immunomodulation for patients with autoimmune diseases,” said Alan Glicklich, M.D., Chief Medical Officer of Nuvig. “Dosing the first patient in our Phase 2 CIDP trial marks an important step forward in our mission to deliver targeted, mechanism-based immunomodulation for patients with autoimmune diseases,” said Alan Glicklich, M.D., Chief Medical Officer of Nuvig Therapeutics. “We are encouraged by the safety and pharmacodynamic data observed in our Phase 1 study and look forward to evaluating NVG-2089 in individuals living with CIDP, a condition that remains underserved by currently available therapies.” The Phase 2 study, called INVGOR, is a multicenter, global trial evaluating the safety, tolerability, and potential clinical benefit of NVG-2089 in up to 60 participants with CIDP. The trial includes patients currently treated with intravenous immunoglobulin (IVIg) who will transition to NVG-2089 and patients who have not previously been treated. The INVGOR trial is being conducted at approximately 40 sites globally. It will evaluate the safety and tolerability of NVG-2089, as well as evaluating the percentage of treatment naive patients achieving evidence of clinical improvement (ECI) at Week 14, and the percentage of IVIg treatment experienced patients achieving ECI at week 14 or stability of disease as measured by adjusted INCAT score between weeks 4 and 14. “There remains a considerable unmet need for CIDP therapies that are effective, non-immunosuppressive, well tolerated, and more convenient than current therapies,” said Jeffrey Allen, M.D., Professor of Neurology at the University of Minnesota Medical School. “We welcome the development of new treatment options such as NVG-2089 that aim to address these limitations and improve patient outcomes.” Presentation of the Phase 1 findings at the upcoming PNS meeting reflects the continued clinical momentum behind NVG-2089. In the Phase 1 study, NVG-2089 was well tolerated, with no serious adverse events, no severe adverse events, and no discontinuations due to adverse events. About NVG-2089 NVG-2089 is a recombinant human IgG1-Fc fusion protein designed to mimic the key immunomodulatory mechanisms of intravenous immunoglobulin (IVIg), the current standard of care for a range of autoimmune diseases. Unlike plasma-derived IVIg, NVG-2089 is produced recombinantly, offering the potential for improved consistency, scalability, and patient convenience. By selectively engaging anti-inflammatory pathways without broadly suppressing the immune system, NVG-2089 is being developed as a next-generation alternative to IVIg with the goal of addressing its limitations in supply, tolerability, and administration burden. About Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological autoimmune disorder characterized by progressive weakness and impaired sensory function in the legs and arms. Symptoms typically include symmetrical muscle weakness leading to difficulties with walking, climbing stairs, and performing fine motor tasks. Sensory disturbances such as numbness, tingling, or burning sensations. Additionally, diminished or absent reflexes are a common clinical finding. Fatigue is frequent, significantly impacting the patient’s quality of life. CIDP symptoms can vary in severity and may progress over several months. Diagnosis is typically confirmed through nerve conduction studies, which reveal demyelination, and cerebrospinal fluid analysis showing elevated protein levels. About Nuvig Therapeutics Nuvig Therapeutics is a clinical-stage biotechnology company that is advancing an innovative and transformational pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases. The Company’s lead investigational drug candidate, NVG-2089, is an engineered Fc fragment designed to precisely target type II Fc receptors. When NVG-2089 binds to its target, it upregulates the expression of FcgRIIb and causes the expansion of T regulatory cells and the downregulation of numerous inflammatory pathways. Nuvig is based in Menlo Park, California. For more information, please visit www.nuvigtherapeutics.com.

Phase 1ImmunotherapyPhase 2Clinical Result

14 May 2025

·www.prnewswire.com

Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS

LUND, Sweden, May 14, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) at the Peripheral Nerve Society (PNS) Annual Meeting, taking place 17-20 May in Edinburgh, Scotland. Hansa communicated the results from the 15-HMedIdeS-09 study in December 2024. Professor Shahram Attarian, Head of Department of Neuromuscular Diseases and ALS, Hopitaux Universitaires de Marseille (APHM) and International Coordinating Principal Investigator will present data from 15-HMedIdeS-09 Phase 2 study at the 2025 PNS Annual Meeting. Hitto Kaufmann, Chief R&D Officer, Hansa Biopharma said, "We are pleased to be able to share more detail around the positive data from our 15-HMedIdeS-09 Phase 2 study, which demonstrated the significant potential imlifidase could have in combination with standard of care IVIg for patients with GBS. We know that IgG is a key driver of inflammatory attacks on peripheral nerves and has been clinically linked to the severity and progression of GBS, and that there is a clear and urgent need for new and faster treatment options in GBS. This data offers meaningful insights to help advance the understanding of IgG in GBS and improve patient care." Hansa's Phase 2 15-HMedIdes-09 open-label, single arm study was performed across multi-centers in the UK, France, and the Netherlands evaluating the safety, tolerability, and efficacy of a single dose of imlifidase (0.25 mg/kg) in 30 adult GBS patients in combination with standard of care (SoC) intravenous immunoglobulin (IVIg). The administration of imlifidase prior to SoC in patients with GBS was considered to be safe and well tolerated. --- ENDS --- Contacts for more information: Evan Ballantyne, Chief Financial Officer [email protected] Stephanie Kenney, VP Global Corporate Affairs [email protected] Notes to editors About imlifidase Imlifidase is a unique antibody-cleaving enzyme originating from Streptococcus pyogenes that specifically targets IgG and inhibits IgG-mediated immune response.1 It has a rapid onset of action, cleaving IgG-antibodies and inhibiting their activity within hours after administration. Imlifidase has conditional marketing approval in Europe and is marketed under the trade name IDEFIRIX® for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.1 About imlifidase and autoimmune diseases Autoimmune diseases form a group of serious diseases caused by the immune system attacking the body. In many autoimmune diseases the immune system mistakenly recognizes the body's own proteins, as foreign and mounts an immune response, creating antibodies to attack the body's own cells and tissues.2-4 Pathogenic IgG can contribute to a broad spectrum of autoimmune diseases. Hansa Biopharma is exploring how imlifidase and HNSA-5487 may be able to prevent or slow the progression of these diseases and their debilitating, life-threatening symptoms. Imlifidase is currently being studied in the following autoimmune diseases: anti-glomerular basement membrane (anti-GBM) disease and Guillain-Barré Syndrome (GBS). HNSA-5487 is moving quickly into the clinical phase focusing on patients with myasthenia gravis (MG) and potentially other neuro-autoimmune diseases. About Guillain-Barré Syndrome Guillain-Barré Syndrome (GBS) is a rare, acute, paralyzing, inflammatory disease of the peripheral nervous system caused by the immune system damaging nerve cells and structures. It affects 1-2 in 100,000 people annually.5 In GBS, rapid onset and progression of muscle weakness occurs and can lead to severe paralysis of the arms and legs. Approximately 25 percent of patients require mechanical ventilation for days to months and 20 percent are unable to walk after six months.6-8 Even with current standard of care - either plasma exchange or IVIg therapy - GBS is fatal in 3-7% of cases.6-8 Most GBS patients also have sensory disturbance (tingling or numbness or ataxia) and pain, and some patients have double vision or problems with swallowing. GBS may also involve the respiratory muscles, leading to intensive care unit (ICU) admission and mechanical ventilation.9 About Hansa Biopharma Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at and follow us on LinkedIn. ©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved. References European Medicines Agency. Idefirix® summary of product characteristics. Available at: . Angum F, et al. The Prevalence of Autoimmune Disorders in Women: A Narrative Review. Cureus. 2020 May 13;12(5):e8094. doi: 10.7759/cureus.8094. Wang L, et al. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015 Oct;278(4):369-95. doi: 10.1111/joim.12395. Ma H, Murphy C, Loscher CE and O'Kennedy R (2022) Autoantibodies – enemies, and/or potential allies? Front. Immunol. 13:953726. doi: 10.3389/fimmu.2022.953726 McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32(2):150-63. doi: 10.1159/000184748. Epub 2008 Dec 17. PMID: 19088488.Fletcher D, et al. Neurology. 2000 27;54(12):2311-5 Leonhard SE, Papri N, Querol L, Rinaldi S, Shahrizaila N, Jacobs BC. Guillain-Barré syndrome. Nat Rev Dis Primers. 2024 Dec 19;10(1):97. doi: 10.1038/s41572-024-00580-4. PMID: 39702645. Fletcher DD, Lawn ND, Wolter TD, Wijdicks EF. Long-term outcome in patients with Guillain-Barre syndrome requiring mechanical ventilation. Neurology. 2000;54(12):2311–5. van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014 Aug;10(8):469-82. doi: 10.1038/nrneurol.2014.121. Epub 2014 Jul 15. PMID: 25023340. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016 Aug 13;388(10045):717-27. doi: 10.1016/S0140-6736(16)00339-1. Epub 2016 Mar 2. PMID: 26948435. This information was brought to you by Cision The following files are available for download: SOURCE Hansa Biopharma AB WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Clinical ResultDrug Approval

12 May 2025

·pipelinereview.com

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

WALTHAM, MA, USA I May 12, 2025 I Invivyd, Inc. (Nasdaq: IVVD) today announced it has initiated a discovery program for a measles monoclonal antibody (mAb). Multiple healthcare providers (HCPs) who are treating active measles and monitoring contacts and outbreaks have inquired directly to Invivyd about the possibility of accessing such a medicine, as there are no currently approved therapies for measles or for post-exposure prophylaxis. Measles monoclonal neutralizing antibody discovery efforts would join current Invivyd discovery programs for next-generation COVID-19, respiratory syncytial virus (RSV), and influenza mAbs designed to treat acute infection or provide a high-quality alternative to vaccination. There are currently no anti-viral treatments for measles. Clinicians have limited options for treatment of individuals sick with measles including high-dose Vitamin A, which is useful to support recovery from measles infections among children who are Vitamin A deficient, and human donor-derived pooled plasma immune globulin (IG) administered via IV (IVIG) to treat active phase measles. Both therapies have limitations for treatment, in addition to not being approved, well-characterized clinical tools: Vitamin A can be hepatotoxic, and IVIG is a non-uniform, polyclonal collection of antibodies collected and pooled from many donors and is poorly suited for widespread use. Standard measles vaccines confer excellent, long-lasting protection from disease and are the most important tools to prevent measles infection but have important limitations in post-exposure prophylaxis and are increasingly underutilized by sizeable populations in America due to restricted healthcare access or religious or personal views on the use of vaccines in general. Recent research published in the Journal of the American Medical Association (JAMA) estimates the potential health effects of declining vaccine uptake and highlights the enormous health consequences to Americans associated with the reestablishment of previously eradicated pathogens such as measles. Acute measles infection involves clinical features of varying severity, including fevers, pneumonia, encephalitis, and high-risk of secondary bacterial infections, with one in four infections leading to hospitalization and one in every 1,000 causing death. The virus deletes immunological memory, creating an immunological amnesia that enhances risk of disease against all infections for years. One in a few thousand cases will cause a 100% fatal deterioration of brain tissue called subacute sclerosing panencephalitis approximately 7-10 years after infection. “Despite effective vaccines, measles outbreaks are increasing globally, including in the U.S. where our elimination status is at risk. With over 20 million unvaccinated Americans in the U.S., and hundreds of millions globally, the burden of measles is high and poised to get worse. There is a huge need for effective treatments,” commented Dr. Michael Mina, MD, PhD, an infectious disease and vaccination expert, previously Professor of Epidemiology and Immunology at Harvard University School of Public Health. “A monoclonal antibody is a particularly attractive therapeutic option for many reasons: antibodies against measles can be highly neutralizing and thus able to rapidly stop infection; they can avoid toxicities and drug-drug interactions that accompany small molecule approaches; and, finally, monoclonal antibodies can serve as a critical prophylaxis tool for at-risk populations. In addition to treating acute infection, pre- and post-exposure prophylaxis may be especially important for children too young to be vaccinated, the immune compromised who cannot be vaccinated, and the elderly, whose immune protection may have waned, and as prophylaxis for people who are otherwise unvaccinated during measles outbreaks.” “A measles monoclonal antibody may be an increasingly important therapeutic option in the coming years. Invivyd’s core strategy is to use best-in-class pharmaceutical monoclonal antibodies to lower the burden of viral infectious diseases,” commented Marc Elia, Chairman of the Invivyd Board of Directors. “Measles (rubeola) is an important potential therapeutic target and an excellent fit with our integrated capabilities in antibody discovery, development, and commercialization. Our goal is to discover and develop a safe, convenient, highly effective mAb against measles with a best-in-class profile that can be easily adopted in contemporary clinical practice. We will look forward to updating on our progress later this year.” About Invivyd Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more. SOURCE: Invivyd

Vaccine

100 Deals associated with Human Normal Immunoglobulin (The Japan Blood Products Organization)

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Graft Rejection	Japan	The Japan Blood Products Organization	24 Sep 2024
Guillain-Barre Syndrome	Japan	The Japan Blood Products Organization	08 Feb 2017
Pemphigoid, Bullous	Japan	The Japan Blood Products Organization	27 Jul 2016
Otitis Media	Japan	The Japan Blood Products Organization	02 Feb 2015
Pemphigus	Japan	The Japan Blood Products Organization	05 Aug 2013
Myasthenia Gravis	Japan	The Japan Blood Products Organization	26 Sep 2011
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	Japan	The Japan Blood Products Organization	07 Feb 2011
Dermatomyositis	Japan	The Japan Blood Products Organization	27 Oct 2010
Polymyositis	Japan	The Japan Blood Products Organization	27 Oct 2010
Mucocutaneous Lymph Node Syndrome	Japan	The Japan Blood Products Organization	31 Jan 1996
Agammaglobulinemia	Japan	The Japan Blood Products Organization	28 Jun 1991
Infectious Diseases	Japan	The Japan Blood Products Organization	28 Jun 1991
Purpura, Thrombocytopenic, Idiopathic	Japan	The Japan Blood Products Organization	28 Jun 1991

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Abortion, Habitual	Phase 3	Japan	The Japan Blood Products Organization	03 Jun 2014
Kidney Failure, Chronic	Phase 3	Japan	The Japan Blood Products Organization	01 Nov 2013
Autoimmune Diseases	Preclinical	United States	Vanderbilt University School of Medicine	30 Oct 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EHA2024	Not Applicable	-	25	IVIG 400mg/kg	gmlsennapg(xnhsgjadwi) = cdwsuwrcae jfuvcuxryu (pcvxfxwfrw, 1 - 000-10 to 500) View more	Positive	14 May 2024
				Dexamethasone 10mg/m2	gmlsennapg(xnhsgjadwi) = jgusurdzpc jfuvcuxryu (pcvxfxwfrw, 1 - 000-10 to 500) View more
ASH2023	Not Applicable	Thrombocytopenia	651	IVIG	qfuwvtqmch(giqkeecjle) = obmirdkvrk szmfgprwzs (eejdjrmtdf ) View more	-	10 Dec 2023
ISN WCN2023	Not Applicable	Polyomavirus Infections	-	IVIG	ncwuqqqtjy(amthlpvhtg) = yoggopcsfd vlsxpdbzzq (owkvhashzu ) View more	-	01 Mar 2023
				No IVIG	ncwuqqqtjy(amthlpvhtg) = jpsnnuxkny vlsxpdbzzq (owkvhashzu ) View more
AAAAI2023	Not Applicable	decreased IgA levels \| concurrent treatment with an immunomodulating agent \| prior reported drug-allergy ... View more	15	IVIG infusion	wceiwkzxdh(yujazogpmk) = cojhrbnlln krooigdpnp (qnqfycclms )	Positive	01 Feb 2023
AAO2022	Not Applicable	Pain \| Peripheral Nervous System Diseases auto-/dysimmune antibodies	-	IVIG	zwixcfuaqf(ryontgadkd) = Four patients discontinued treatment before follow-up due to side effects najjmoqdal (himzgjlldz ) View more	Positive	29 Sep 2022
ProCID study (AAN2022)	Not Applicable	Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	142	High dose IVIG (2.0g/kg)	mzpbnbahap(ymsioioqmr) = allergic dermatitis bpbouzkaqy (vbtudfixzi ) View more	-	03 May 2022
AAN2022	Not Applicable	Muscle Weakness	-	IVIG	ghcoqgblvv(xxhqdpewvr) = ddglyeoxta ajhbqdmxjv (hltfvecbbd, 1.19 - 2.10)	-	03 May 2022
				IVIG	yllnfwkbbo(wfddqwbbxs) = zisxupmzar bvxrmoxngy (trfjknsucf ) View more
AAAAI2022	Not Applicable	Immunologic Deficiency Syndromes	53	PCV13IVIG (PCV13 vaccination)	veocwvfedi(oafokuyehr) = jwqljfksnk itnahgrijd (pagrklzcga )	-	01 Feb 2022
				PPSV23IVIG (PPSV23 vaccination)	ijnkzzutum(ivxucyfcrq) = urgcluupip bfkgunfthy (yekrqhamys )
P5.2-072 (AAN2019)	Not Applicable	anti-aquaporin 4 (AQP4) antibodies \| anti-myelin oligodendrocyte glycoprotein (MOG) antibodies \| anti-Human 3-hydroxy-3-methylglutaryl-Coenzyme A reductase (HMGCR) antibodies ... View more	-	IVIg preparations	hiapzlydbi(dvivqljexs) = ykpnqcpjjg owubhutquj (qrutnmynfo, 41 - 816)	-	09 Apr 2019
P5.2-073 (AAN2019)	Not Applicable	-	-	IVIG	tgnvbpwzuv(izcjzqhwjw) = kiwkeefknp owostvmbgr (itvpznsjzp )	-	09 Apr 2019
				IVIG	tgnvbpwzuv(izcjzqhwjw) = xtfpquqchw owostvmbgr (itvpznsjzp )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Human Normal Immunoglobulin (The Japan Blood Products Organization)

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation